Target Name: TENT4B
NCBI ID: G64282
Review Report on TENT4B Target / Biomarker Content of Review Report on TENT4B Target / Biomarker
TENT4B
Other Name(s): PAPD5_HUMAN | TENT4B variant 1 | non-canonical poly(A) RNA polymerase PAPD5 | PAP associated domain containing 5 | Terminal nucleotidyltransferase 4B | Non-canonical poly(A) RNA polymerase PAPD5 | Topoisomerase-related function protein 4-2 | terminal guanylyltransferase | TRF4-2 | Terminal uridylyltransferase 3 | PAPD5 | Terminal nucleotidyltransferase 4B, transcript variant 1 | topoisomerase-related function protein 4-2 | terminal nucleotidyltransferase 4A | TUT3 | terminal uridylyltransferase 3 | Terminal nucleotidyltransferase 4A | PAP-associated domain-containing protein 5 | Terminal nucleotidyltransferase 4B (isoform a) | TUTase 3 | terminal nucleotidyltransferase 4B | Terminal guanylyltransferase | poly(A) RNA polymerase D5, non-canonical

TENT4B: A Potential Drug Target and Biomarker

TENT4B (PAPD5_HUMAN), a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys, has been identified as a potential drug target or biomarker. The protein is a part of the PAPD5 gene, which encodes a protein known as protamine phosphatase 5. This protein is involved in a variety of cellular processes, including the regulation of protein function, DNA replication, and cell signaling.

Research has shown that TENT4B is involved in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. It is also implicated in the regulation of cellular processes that are important for brain function, such as the formation of new neurons and the regulation of neurotransmitter release.

One of the key challenges in studying TENT4B is its highly conserved nature. This protein is highly similar across different species, which makes it difficult to study its function in specific contexts. However, researchers have been able to use techniques such as mass spectrometry and biochemical assays to study its expression and activity in various cellular contexts.

In addition to its potential as a drug target, TENT4B has also been identified as a potential biomarker for a variety of diseases. The protein is often expressed at low levels in many tissues, which makes it difficult to study its effects in specific contexts. However, researchers have been able to use techniques such as RNA sequencing and western blotting to study its expression in various tissues and conditions.

One potential application of TENT4B as a drug target is its involvement in the regulation of neurotransmitter release. neurotransmitters are important for transmitting signals in the brain, and their release is regulated by a variety of factors, including the activity of TENT4B. Researchers have identified that TENT4B is involved in the regulation of neurotransmitter release, and that this function may be important for the treatment of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.

Another potential application of TENT4B as a drug target is its involvement in the regulation of protein function. TENT4B has been shown to be involved in the regulation of protein function in various cellular contexts, and this function may be important for the treatment of diseases that are characterized by the overuse or dysfunction of proteins. For example, TENT4B has been shown to be involved in the regulation of protein function in the development of neurodegenerative diseases, and this may make it an attractive target for the treatment of these conditions.

In addition to its potential as a drug target or biomarker, TENT4B is also of interest as a potential therapeutic agent. Researchers have been able to use techniques such as RNA interference and cell-based assays to study the effects of TENT4B in various cellular contexts, and have identified that this protein has the potential to be a therapeutic agent for a variety of conditions.

Overall, TENT4B (PAPD5_HUMAN) is a protein that has the potential to be a drug target or biomarker for a variety of diseases. Its highly conserved nature and involvement in cellular processes that are important for brain function make it an attractive target for the study of its function in various contexts. Further research is needed to fully understand the function of TENT4B and its potential as a therapeutic agent.

Protein Name: Terminal Nucleotidyltransferase 4B

Functions: Terminal nucleotidyltransferase that catalyzes preferentially the transfert of ATP and GTP on RNA 3' poly(A) tail creating a heterogeneous 3' poly(A) tail leading to mRNAs stabilization by protecting mRNAs from active deadenylation (PubMed:21788334, PubMed:30026317). Also functions as a catalytic subunit of a TRAMP-like complex which has a poly(A) RNA polymerase activity and is involved in a post-transcriptional quality control mechanism. Polyadenylation with short oligo(A) tails is required for the degradative activity of the exosome on several of its nuclear RNA substrates. Doesn't need a cofactor for polyadenylation activity (in vitro) (PubMed:21788334, PubMed:21855801). Required for cytoplasmic polyadenylation of mRNAs involved in carbohydrate metabolism, including the glucose transporter SLC2A1/GLUT1 (PubMed:28383716). Plays a role in replication-dependent histone mRNA degradation, probably through terminal uridylation of mature histone mRNAs. May play a role in sister chromatid cohesion (PubMed:18172165). Mediates 3' adenylation of the microRNA MIR21 followed by its 3'-to-5' trimming by the exoribonuclease PARN leading to degradation (PubMed:25049417). Mediates 3' adenylation of H/ACA box snoRNAs (small nucleolar RNAs) followed by its 3'-to-5' trimming by the exoribonuclease PARN which enhances snoRNA stability and maturation (PubMed:22442037)

The "TENT4B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TENT4B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

TENT5A | TENT5B | TENT5C | TENT5C-DT | TENT5D | TEP1 | TEPP | TEPSIN | TERB1 | TERB2 | TERC | TERF1 | TERF1P3 | TERF2 | TERF2IP | TERLR1 | TERT | TES | TESC | TESK1 | TESK2 | TESMIN | TESPA1 | TET1 | TET2 | TET2-AS1 | TET3 | Tetraspanin | TEX10 | TEX101 | TEX11 | TEX12 | TEX13A | TEX13B | TEX13C | TEX14 | TEX15 | TEX19 | TEX2 | TEX21P | TEX22 | TEX26 | TEX261 | TEX264 | TEX28 | TEX29 | TEX30 | TEX33 | TEX35 | TEX36 | TEX36-AS1 | TEX37 | TEX38 | TEX41 | TEX43 | TEX44 | TEX45 | TEX46 | TEX47 | TEX48 | TEX49 | TEX50 | TEX52 | TEX53 | TEX55 | TEX56P | TEX9 | TF | TFAM | TFAMP1 | TFAP2A | TFAP2A-AS1 | TFAP2A-AS2 | TFAP2B | TFAP2C | TFAP2D | TFAP2E | TFAP4 | TFB1M | TFB2M | TFCP2 | TFCP2L1 | TFDP1 | TFDP1P2 | TFDP2 | TFDP3 | TFE3 | TFEB | TFEC | TFF1 | TFF2 | TFF3 | TFG | TFIID Basal Transcription Factor Complex | TFIIIC2 complex | TFIP11 | TFIP11-DT | TFPI | TFPI2 | TFPT